MRI Surveillance Outperforms Prophylactic Cranial Irradiation in Small-Cell Lung Cancer Trial

The international phase 3 SWOG S1827 MAVERICK trial, presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer, demonstrated that brain magnetic‑resonance imaging (MRI) surveillance alone yields superior cognitive failure‑free survival compared with a regimen that combines MRI surveillance with prophylactic cranial irradiation (PCI) in patients with small‑cell lung cancer (SCLC). The study enrolled a broad cohort of SCLC patients and randomly assigned them to either routine brain MRI monitoring or to MRI monitoring plus PCI, a preventive radiation therapy traditionally used to reduce the risk of brain metastases but associated with notable neurocognitive toxicity.

The results showed a statistically significant advantage for the MRI‑only arm, indicating fewer cognitive declines without compromising overall disease control. Based on these findings, researchers advocated adopting brain MRI surveillance as the new standard of care for SCLC, replacing routine PCI. The data are expected to influence clinical guidelines and practice patterns, emphasizing a strategy that preserves neurological function while maintaining effective oncologic surveillance.